Radiometals: Novel methods in production, radiochemistry and application

放射性金属：生产、放射化学和应用的新方法

• 批准号: RGPIN-2016-04413
• 负责人: Schaffer, Paul
• 金额: $ 2.62万
• 依托单位: Simon Fraser University
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=632360
• 关键词: Radiometals; Novel; methods; production; radiochemistry

Radioisotopes can be produced either in nuclear reactors or particle accelerators, with the former having long-defined the global production paradigm due to the higher power of reactors and relative scarcity of compact, commercially available accelerators (cyclotrons). However, the global landscape is changing; cyclotron-based isotope production is now more prevalent, while reactors around the world are scheduled to go off-line within the next few years. This perceived threat to our isotope supply is re-defining how and where the isotopes most vital for use in science and medicine are made. Canada has long recognized this issue and has invested heavily in cyclotron technology. This country now boasts one of the most advanced particle accelerator infrastructures in the world, and with it, a strong radiopharmaceutical community.

放射性同位素既可以在核反应堆中生产，也可以在粒子加速器中生产，由于反应堆的功率更高，而紧凑的商用加速器（回旋加速器）相对稀缺，前者长期以来一直是全球生产模式的定义。然而，全球格局正在发生变化；基于回旋加速器的同位素生产现在更为普遍，而世界各地的反应堆计划在未来几年内停产。这种对同位素供应的威胁正在重新定义科学和医学中最重要的同位素的制造方式和地点。加拿大早就认识到这个问题，并在回旋加速器技术上投入了大量资金。这个国家现在拥有世界上最先进的粒子加速器基础设施之一，随之而来的是一个强大的放射性制药社区。